BIO.B vs. FTV, VLTO, TER, RVTY, AVTR, NVMI, VNT, ST, MIR, and CAMT
Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Fortive (FTV), Veralto (VLTO), Teradyne (TER), Revvity (RVTY), Avantor (AVTR), Nova (NVMI), Vontier (VNT), Sensata Technologies (ST), Mirion Technologies (MIR), and Camtek (CAMT). These companies are all part of the "measuring and control equipment" industry.
Bio-Rad Laboratories vs.
Bio-Rad Laboratories (NYSE:BIO.B) and Fortive (NYSE:FTV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, community ranking, valuation, media sentiment, institutional ownership, risk, earnings and dividends.
Fortive has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Fortive, indicating that it is currently the more affordable of the two stocks.
Fortive has a consensus target price of $81.92, indicating a potential upside of 16.83%. Given Fortive's stronger consensus rating and higher probable upside, analysts plainly believe Fortive is more favorable than Bio-Rad Laboratories.
Bio-Rad Laboratories has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. Comparatively, Fortive has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.
In the previous week, Fortive had 24 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 24 mentions for Fortive and 0 mentions for Bio-Rad Laboratories. Fortive's average media sentiment score of 1.27 beat Bio-Rad Laboratories' score of 0.00 indicating that Fortive is being referred to more favorably in the news media.
0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 94.9% of Fortive shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 1.0% of Fortive shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Fortive received 289 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. Likewise, 59.57% of users gave Fortive an outperform vote while only 57.60% of users gave Bio-Rad Laboratories an outperform vote.
Fortive has a net margin of 13.36% compared to Bio-Rad Laboratories' net margin of -71.86%. Fortive's return on equity of 13.15% beat Bio-Rad Laboratories' return on equity.
Summary
Fortive beats Bio-Rad Laboratories on 17 of the 18 factors compared between the two stocks.
Get Bio-Rad Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BIO.B vs. The Competition
Bio-Rad Laboratories Competitors List
Related Companies and Tools
This page (NYSE:BIO.B) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy BIO.B Stock Free BIO.B Stock Alerts